Andarine
 |
|
| Clinical data | |
|---|---|
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
|
|
| Synonyms | Acetamidoxolutamide; Androxolutamide; GTx-007; S-4 |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| ChEMBL | |
| ECHA InfoCard | 100.230.653 |
| Chemical and physical data | |
| Formula | C19H18F3N3O6 |
| Molar mass | 441.357 g/mol |
| 3D model (JSmol) | |
|
|
|
|
  (what is this?) (verify) |
|
Andarine (GTx-007, S-4) is an investigational selective androgen receptor modulator (SARM) developed by GTX, Inc for treatment of conditions such as muscle wasting, osteoporosis and benign prostatic hypertrophy,[1] using the nonsteroidal antiandrogen bicalutamide as a lead compound.[2]
Andarine is an orally active partial agonist for androgen receptors. It is less potent in both anabolic and androgenic effects than other SARMs. In an animal model of benign prostatic hypertrophy, andarine was shown to reduce prostate weight with similar efficacy to finasteride, but without producing any reduction in muscle mass or anti-androgenic side effects.[3] This suggests that it is able to competitively block binding of dihydrotestosterone to its receptor targets in the prostate gland, but its partial agonist effects at androgen receptors prevent the side effects associated with the anti-androgenic drugs traditionally used for treatment of BPH.[4]
See also[edit]
References[edit]
- ^ Hott JL, Borkman RF (November 1989). "The non-fluorescence of 4-fluorotryptophan". The Biochemical Journal. 264 (1): 297–9. PMC 1133577
. PMID 2604714. doi:10.1124/jpet.102.040840. - ^ Chen J, Kim J, Dalton JT (June 2005). "Discovery and therapeutic promise of selective androgen receptor modulators". Molecular Interventions. 5 (3): 173–88. PMC 2072877 . PMID 15994457. doi:10.1124/mi.5.3.7.
- ^ GGao W, Kearbey JD, Nair VA, Chung K, Parlow AF, Miller DD, Dalton JT (December 2004). "Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia". Endocrinology. 145 (12): 5420–8. PMC 2098692 . PMID 15308613. doi:10.1210/en.2004-0627.
- ^ Gao W, Kim J, Dalton JT (August 2006). "Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands". Pharmaceutical Research. 23 (8): 1641–58. PMC 2072875 . PMID 16841196. doi:10.1007/s11095-006-9024-3.
 |
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
